首页> 外文OA文献 >An investigation into development of a stable aqeous suspension of Metronidazole Benzoate for oral use
【2h】

An investigation into development of a stable aqeous suspension of Metronidazole Benzoate for oral use

机译:口服甲硝唑苯甲酸盐稳定水悬浮液的研制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Metronidazole is a synthetic, nitroimidazole-derivative antibacterial and antiprotozoal agent (ed. McEvoy, 2001). It has been reported that crystallization occurs in aqueous suspensions of metronidazole benzoate, a bland-tasting prodrug of metronidazole, as a result of conversion from the anhydrous to the monohydrate form, thereby compromising the stability and clinical efficacy of the substance due to the particle size growth (Hoelgaard & Moller, 1983). A generic South African based pharmaceutical company commenced formulation of an aqueous metronidazole benzoate suspension and experienced problems with crystallization that occurred in products stored at 2 to 8 °C. This study aimed to continue development of the product in order to identify a formulation that prevents formation of the hydrate form of metronidazole benzoate and the accompanying crystal growth. A variety of metronidazole benzoate suspensions were manufactured on a laboratory scale using a number of natural and synthetic suspending agents, including magnesium aluminium silicate, povidone K90, xanthan gum and Avicel® RC-591 (microcrystalline cellulose and carboxymethylcellulose sodium), over a range of concentrations. Analytical quantification methods were developed and validated, and the physicochemical properties of the raw material and finished products were fully characterized. Rheological tests were performed in order to characterize the suspension flow properties. Real-time and accelerated stability studies and a temperature cycle study were conducted in accordance with the International Conference on Harmonization (ICH) guidelines. Conversion of metronidazole benzoate to the monohydrate form took place in suspensions containing xanthan gum 0.65 percent m/v under real-time and accelerated storage conditions. The suspensions containing Avicel® RC-591 were found to be physically and chemically stable after the temperature cycle and over the 12-week period whilst stored at 25 ºC / 60 percent RH and 5 ºC. The suspensions were chemically stable whilst stored at 40 ºC / 75 percent RH but showed sedimentation at this accelerated condition. The metronidazole benzoate contained in these products remained in the anhydrous state under all storage conditions and were consequently concluded to be the most stable formulations out of all the products analyzed in the current study. The suspending agent system consisting of microcrystalline cellulose and carboxymethylcellulose sodium thus shows promise in preventing the conversion of metronidazole benzoate from the anhydrate to the monohydrate form, thereby inhibited the subsequent increase in particle size due to crystal growth.
机译:甲硝唑是一种合成的,硝基咪唑衍生物的抗菌和抗原生动物剂(McEvoy编辑,2001年)。据报道,由于甲硝唑从无水形式转变为一水合物形式,在甲硝唑的温和的前药中,在甲硝唑苯甲酸酯的水性悬浮液中发生结晶,从而由于粒径而损害了该物质的稳定性和临床功效。增长(Hoelgaard&Moller,1983)。一家总部位于南非的通用制药公司开始配制甲硝唑苯甲酸酯水溶液悬浮液,并在2至8°C的储存条件下出现结晶问题。这项研究旨在继续开发该产品,以便确定可防止甲硝唑苯甲酸酯的水合物形式形成以及伴随晶体生长的制剂。在实验室规模上使用许多天然和合成的悬浮剂制造了各种甲硝唑苯甲酸酯悬浮液,包括硅酸铝镁,聚维酮K90,黄原胶和RC-591(微晶纤维素和羧甲基纤维素钠)。浓度。开发并验证了分析定量方法,并充分表征了原材料和成品的理化性质。进行流变测试以表征悬浮液流动特性。根据国际协调会议(ICH)指南进行了实时和加速稳定性研究以及温度循环研究。甲硝唑苯甲酸酯向一水合物形式的转化是在实时和加速存储条件下,在含有黄麻胶0.65%m / v的悬浮液中进行的。发现含有Avicel®RC-591的悬浮液在温度循环后和在过去12周的时间内保持物理和化学稳定性,同时在25ºC/ 60%RH和5ºC下储存。悬浮液在40ºC/ 75%相对湿度下仍保持化学稳定性,但在这种加速条件下显示出沉淀。这些产品中所含的甲硝唑苯甲酸酯在所有储存条件下均保持无水状态,因此被认为是目前研究中所有产品中最稳定的制剂。因此,由微晶纤维素和羧甲基纤维素钠组成的悬浮剂体系显示出防止甲硝唑苯甲酸酯从无水物转化为一水合物形式的前景,从而抑制了随后由于晶体生长而引起的粒度增加。

著录项

  • 作者

    Zietsman Sharon Lynne;

  • 作者单位
  • 年度 2005
  • 总页数
  • 原文格式 PDF
  • 正文语种 English
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号